FCGR1A anticorps (FITC)

N° du produit ABIN1302937

Détail du produit anti-FCGR1A anticorps (FITC)

Antigène: FCGR1A (Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) (FCGR1A))

Reactivité: Humain, Non-Human Primate

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FCGR1A est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Specificité: The mouse monoclonal antibody 10.1 recognizes an extracellular epitope on CD64/FcgammaRI, a 72 kDa single chain type I glycoprotein, that is expressed on monocytes/macrophages, dendritic cells, and activated granulocytes. The epitope is sensitive to formalin fixation.

Réactivité croisée (Details): Human, Non-Human Primates

Purification: Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogène: Rheumatoid synovial fluid cells and fibronectin purified human monocytes

Clone: 10-1

Isotype: IgG1 kappa

Information d'application

Indications d'application: Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Commentaires:

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

Restrictions: For Research Use only

Stockage

Reconstitution: No reconstitution is necessary.

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Do not freeze.
Avoid prolonged exposure to light.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Références pour anticorps anti-FCGR1A (FITC) (ABIN1302937)

Devaraj, Davis, Simon, Jialal: "CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions." dans: American journal of physiology. Heart and circulatory physiology, Vol. 291, Issue 3, pp. H1170-6, (2006) (PubMed).

Devaraj, Du Clos, Jialal: "Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects." dans: Arteriosclerosis, thrombosis, and vascular biology, Vol. 25, Issue 7, pp. 1359-63, (2005) (PubMed).

Roura-Mir, Wang, Cheng, Matsunaga, Dascher, Peng, Fenton, Kirschning, Moody: "Mycobacterium tuberculosis regulates CD1 antigen presentation pathways through TLR-2." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 3, pp. 1758-66, (2005) (PubMed).

Beekman, Bakema, van der Linden, Tops, Hinten, van Vugt, van de Winkel, Leusen: "Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin." dans: The Journal of biological chemistry, Vol. 279, Issue 32, pp. 33875-81, (2004) (PubMed).

Sánchez-Torres, García-Romo, Cornejo-Cortés, Rivas-Carvalho, Sánchez-Schmitz: "CD16+ and CD16- human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells." dans: International immunology, Vol. 13, Issue 12, pp. 1571-81, (2001) (PubMed).

Brichard, Varis, Latinne, Deneys, de Bruyere, Leveugle, Cornu: "Intracellular cytokine profile of cord and adult blood monocytes." dans: Bone marrow transplantation, Vol. 27, Issue 10, pp. 1081-6, (2001) (PubMed).

Fadlon, Vordermeier, Pearson, Mire-Sluis, Dumonde, Phillips, Fishlock, Brown: "Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64." dans: Blood, Vol. 91, Issue 1, pp. 266-74, (1998) (PubMed).

Hashimoto, Yamada, Motoyoshi, Akagawa: "Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10." dans: Blood, Vol. 89, Issue 1, pp. 315-21, (1997) (PubMed).

Jayaram, Buckle, Hogg: "The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma." dans: Clinical and experimental immunology, Vol. 75, Issue 3, pp. 414-20, (1989) (PubMed).

Dougherty, Selvendran, Murdoch, Palmer, Hogg: "The human mononuclear phagocyte high-affinity Fc receptor, FcRI, defined by a monoclonal antibody, 10.1." dans: European journal of immunology, Vol. 17, Issue 10, pp. 1453-9, (1987) (PubMed).

Détails sur FCGR1A

Antigène: FCGR1A (Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) (FCGR1A))

Autre désignation: CD64 (FCGR1A Produits)

Synonymes: anticorps CD64, anticorps CD64A, anticorps FCRI, anticorps IGFR1, anticorps FcgammaRI, anticorps Fcgr1, anticorps Fcgr1b, anticorps AI323638, anticorps AV092959, anticorps IGGHAFC, anticorps FCGR1A, anticorps Fc fragment of IgG receptor Ia, anticorps Fc receptor, IgG, high affinity I, anticorps FCGR1A, anticorps Fcgr1a, anticorps Fcgr1

Sujet: Fc fragment of IgG receptor Ia,CD64 (FcgammaRI) is a cell surface receptor for Fc region of IgG. It is composed of specific ligand binding alpha subunit and promiscuous gamma subunit, which is indispensable for tyrosine-based signaling. However, even the alpha subunit can transduce signals leading to cellular effector functions. The isoform FcgammaRIa1 binds human IgG with high affinity, has limited myeloid cell distribution, and a relatively large intracellular domain. Products of related genes include FcgammaRIb and FcgammaRIc isoforms, but these specify low affinity IgG receptors if functionally expressed at all. Besides a role in antigen clearance, FcgammaRI (a1) can potently enhance MHC class I and II antigen presentation in vitro and in vivo.,FcRI, IGFR1, FcgR1A

ID gène: 2209

UniProt: P12314

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process